Assessment of the role of IL6 and IL10 gene polymorphisms as a risk factor for the development of restenosis in patients after implantation of drug-eluting stents

Cover Page

Cite item

Abstract

Relevance. Currently, the number of percutaneous coronary interventions continues to increase, which leads to an increase in the absolute number of restenosis cases, which is the main complication of the long-term postoperative period. The search for risk factors responsible for restenosis and artery re-narrowing mechanisms in order to prevent this complication is an important goal in interventional cardiology. Risk factors for the restenosis development include clinical, angiographic and genetic factors. An active search for biomolecular markers associated with the coronary artery restenosis is currently underway. Objective: to study the role of polymorphic variants C-174G of the IL6 gene and C-819T of the IL10 gene as a risk factor for the development of restenosis in patients after stent implantation. Materials and Methods : The study included 113 patients with stable coronary artery disease, who had previously undergone balloon angioplasty and implantation of drug-eluting stents, and 62 patients with intact arteries that were included to the control group. Statistical data processing was carried out using the R-language program and the SPSS Statistics 20 software package. Results: GG genotype for IL6 gene was associated with the development of coronary artery disease. In the subgroup of patients over 65 years of age and instent restenosis, the GG genotype was significantly less frequent. The homozygous CC genotype for IL10 gene was associated with rapid angiographic in-stent restenosis progression.

About the authors

K. B. Timizheva

Peoples’ Friendship University of Russia (RUDN University)

Author for correspondence.
Email: kalima.bogatyreva@mail.ru
Moscow, Russian Federation

A. V. Aghajanyan

Peoples’ Friendship University of Russia (RUDN University)

Email: kalima.bogatyreva@mail.ru
Moscow, Russian Federation

L. V. Tskhovrebova

Peoples’ Friendship University of Russia (RUDN University); Federal Research and Clinical Center of Physical-Chemical Medicine

Email: kalima.bogatyreva@mail.ru
Moscow, Russian Federation

Z. Kh. Shugushev

Peoples’ Friendship University of Russia (RUDN University); Central clinical hospital «RZD-Medicine»

Email: kalima.bogatyreva@mail.ru
Moscow, Russian Federation

M. M. Azova

Peoples’ Friendship University of Russia (RUDN University)

Email: kalima.bogatyreva@mail.ru
Moscow, Russian Federation

References

  1. Scientific Organizing Committee of the ESSE-RF project. Epidemiology of cardiovascular diseases in various regions of Russia (ESSE-RF). Rationale and design of the study. Preventive medicine. 2013;16(6):25-34.
  2. Levine GN, Bates ER, Blankenship JC, et al. ACCF / AHA / SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll. Cardiol. 2011;58:P.44-122.
  3. Roger L, Go AS, Lloyd-Jones DM., et al. Statistics. Update A Report From the American Heart Association Circulation. 2011.
  4. Fukuda D, Shimada K, Tanaka A, Kawarabayashi T, Yoshiyama M, Yoshikawa J. Circulating monocytes and in-stent neointima after coronary stent implantation. J Am Coll Cardiol. 2004;43(1):18-23.
  5. Sun J, Yu H, Liu H, Pu D, Gao., Jin X, Liu X, Yan A. Correlation of pre-operative circulating inflammatory cytokines with restenosis and rapid angiographic stenotic progression risk in coronary artery disease patients underwent percutaneous coronary intervention with drug-eluting stents. J Clin Lab Anal. 2020;34(3):e23108.
  6. Montone R. A, Niccoli G. Predictive value of C-reactive protein after drug-eluting stent implantation: an update view. Future Cardiol. 2018;14(5):355— 358.
  7. Zurakowski A, Wojakowski W, Dzielski T, Milewski K, GościńskaBis K, Tendera M, Buszman P. Plasma levels of C-reactive protein and interleukin-10 predict late coronary in-stent restenosis 6 months after elective stenting. Kardiol Pol. 2009;67(6):623-30.
  8. Kazmierczak E, Grajek S, Kowal J, Chmara E, Grygier M, Pyda M, et al. Prognostic usefulness of IL-6 and VEGF for the occurrence of changes in coronary arteries of patients with stable angina and implanted stents. Eur Rev Med Pharmacol Sci. 2014;18(15):2169-75.
  9. Kumari R, Kumar S, Ahmad MK, Singh R, Kant Kumar S, Pradhan A, Chandra S, Kumar S. Promoter variants of TNF-α rs1800629 and IL-10 rs1800871 are independently associated with the susceptibility of coronary artery disease in north Indian. Cytokine. 2018;110:131-136.
  10. Yu GI, Cho HC, Cho YK, Park HS, Yoon HJ, Kim HS, et al. Association of promoter region single nucleotide polymorphisms at positions -819C/T and -592C/A of interleukin 10 gene with ischemic heart disease. Inflamm Res. 2012;61(8):899-905.

Copyright (c) 2021 Timizheva K.B., Aghajanyan A.V., Tskhovrebova L.V., Shugushev Z.K., Azova M.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies